San Jose BioCenter

Agenda:
12:00-12:30 PM Lunch, Networking & Registration
12:30-2:00 PM Workshop

You created your own company and have great plans for developing your product, but you need help - smart, hardworking people to help you make your company the next biggest story in your industry. The only problem is, you have been footing most of the bills yourself, and cash is too tight to lure those smart, hardworking people to come work for your company. But, wait! You can give them a piece of your company to own - shares of your stock, an equity stake, a "piece of the pie." Surely, with the success you hope to see in your company's future, that would be a great incentive to come aboard. And that is certainly true, except that structuring those equity incentives is a mine field of complex legal, tax and accounting issues that could get your company and those who you wished to reward in more trouble than any benefit anyone would see from the incentives. An attorney from Howard Rice will discuss the basic issues to be considered in developing an equity incentive program for your company, the latest developments in tools and devices that can be used to accomplish a variety of goals for the program, as well as pitfalls to watch out for in the process.

Join us to learn about:

� the different types of equity incentive awards that a company could use to attract and keep new talent (e.g., stock options, restricted stock, SARs or RSUs);
� the general tax implications for the recipient (e.g., are there tax consequences when the award is granted? vested? exercised? sold?);
� the mechanics of creating and issuing these awards (e.g., required approvals, documents, governmental filings);
� the general accounting consequences for the company; and
� the latest developments in complying with Section 409A of the Internal Revenue Code, the application of which, in governing tax consequences of deferred compensation arrangements, has reached broadly into many other areas of compensatory arrangements, including stock options and even severance agreements.

PRESENTER: Julia Vax.
Julia is a director in the firm�s Business Department, practicing general business, corporate and securities law. Her clients include emerging growth and public companies primarily in the life sciences and technology sectors. Ms. Vax represents issuers of publicly traded securities, privately held companies and founders, issuers and investors in venture capital financings and other financial and strategic transactions. She has represented life science and technology companies at all stages of development, from entrepreneurs to publicly traded entities. She has advised clients in the biopharmaceutical, genomics, medical device, diagnostics, internet and media, software, IP telephony, telecommunications and financial services sectors in all aspects of their corporate development. She has been involved in numerous public and private financing transactions representing companies, investors, underwriters and placement agents. Significant representations have included: Digital River, Inc., PalmSource, Inc., The Charles Schwab Corporation, PlanetOut Inc., World Heart Corporation, Pacific Growth Equities, Inc., Gilead Sciences, Inc., Telik, Inc., Abgenix, Inc., CV Therapeutics, Inc., InterWest Partners, Aberdare Ventures and Redpoint Ventures.

Cost & Registration:
� Regular Price ~ $15 (+Acteva fee)
� SVASE, BioScience Forum, IEEE, & Biotech Weblog members ~ $10 (+Acteva fee)
� SJBC members & affiliates ~ Free (Members and affiliates, please RSVP to Aurelie at [email protected])